Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12587132 | 0.93 | CYP3A4 (0.76) | CYP3A4CYP2C19ALDH1A1PKMKDM4E | |
| SCHEMBL23997508 | 0.92 | PKM (0.60) | CYP3A4CYP2C19ALDH1A1PKMPOLB | |
| SCHEMBL2474562 | 0.91 | ALDH1A1 (0.62) | ALDH1A1PKMKDM4ENPC1RAB9A | |
| SCHEMBL21510171 | 0.89 | PKM (0.54) | CYP3A4CYP2C19ALDH1A1PKMNPC1 | |
| SCHEMBL4108239 | 0.88 | ALDH1A1 (0.67) | CYP3A4CYP2C19ALDH1A1PKMKDM4E | |
| SCHEMBL8200209 | 0.84 | PKM (0.60) | CYP3A4CYP2C19ALDH1A1PKMKDM4E | |
| SCHEMBL30436908 | 0.84 | ALDH1A1 (0.55) | ALDH1A1PKMKDM4ENPC1RAB9A | |
| SCHEMBL14538110 | 0.82 | ALDH1A1 (0.59) | ALDH1A1PKMKDM4ENPC1RAB9A | |
| SCHEMBL4516709 | 0.81 | PKM (0.57) | CYP2C19ALDH1A1PKMKDM4ENPC1 | |
| SCHEMBL3235046 | 0.81 | PKM (0.57) | CYP2C19ALDH1A1PKMKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | Gongwin Biopharm Holdings Co., Ltd. | 2019-10-24 | — | — | US | disclosed |
| US-9782370-B2 | Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma | Gongwin Biopharm Holdings Co., Ltd. (KY) | 2017-10-10 | — | — | US | disclosed |
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | GONGWIN BIOPHARM CO., LTD. (TAIWAN) (TW) | 2017-06-22 | — | — | US | disclosed |
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1212319-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019817-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | ARSA, ABCB1, ABCG2 | CYP3A4 34/4885CYP2C19 70/4885ALDH1A1 689/4885 |
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | ABCD3, CFTR, ADSL | CYP3A4 1125/4885CYP2C19 528/4885ALDH1A1 1243/4885 |
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | GAP43, SLC18A2, GABRE | CYP3A4 1870/4885CYP2C19 2607/4885ALDH1A1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.